Navigation Links
Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences
Date:11/1/2007

BERKELEY, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Michael S. Ostrach, Vice President and Chief Business Officer, will present an overview of the company at two investor conferences in New York City the first week of November. Ostrach will present at the CIBC World Markets 18th Annual Healthcare Conference on Monday, November 5, 2007 at 8:35 a.m. ET (5:35 a.m. PT). In addition, Ostrach will present at the Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, 2007 at 4:45 p.m. ET (1:45 p.m. PT). Both presentations will be webcast.

To access the live audio broadcast and the subsequent archived audio recordings of the company presentation, please log onto the company's website at http://www.dynavax.com under the "Investors'" section.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV(TM), a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.


'/>"/>
SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... KS (PRWEB) , ... September 22, 2017 , ... ... Plus, a nutritional supplement produced by Native Remedies that helps promote pancreatic health ... priority for many individuals. However, some prescription-based approaches can have negative side effects, ...
(Date:9/22/2017)... , ... September 22, 2017 , ... “Letters From Home”: ... people, even the lost, have value to God. “Letters From Home” is the creation ... a member of the President’s Cabinet of Jerry Savelle Ministries International, who has traveled ...
(Date:9/21/2017)... ... ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is Saluted as Young Achiever ... Surgeon Kiranjeet Gill has been awarded as one of the 15th annual 40-under-40 recipients! ... started in 2003 to salute young achievers in Southwest Florida who have distinguished themselves ...
(Date:9/21/2017)... ... September 21, 2017 , ... Hair restoration surgery ... survey conducted by the International Society of Hair Restoration Surgery (ISHRS). ... rose 60 percent, with 635,189 procedures performed in 2016. , "Like other ...
(Date:9/21/2017)... ... 2017 , ... The New England Center for Children® (NECC®), a global leader ... Hung to the Board of Directors. , “The New England Center for Children ... an invaluable addition to our team,” said Vincent Strully, Jr., President and CEO of ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology: